Photo from wikipedia
Key Points Combined targeting of AML patient cells with p38 MAPK and BCL2 inhibitors overcomes monocytic-associated resistance to VEN. Exploiting complementary drug sensitivity profiles with respect to leukemic differentiation state… Click to show full abstract
Key Points Combined targeting of AML patient cells with p38 MAPK and BCL2 inhibitors overcomes monocytic-associated resistance to VEN. Exploiting complementary drug sensitivity profiles with respect to leukemic differentiation state affords enhanced efficacy in AML.
Keywords:
drug;
sensitivity differentiation;
associating drug;
drug sensitivity
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!